The GLP-developed warehouses were disposed of due to "the stabilised nature of the portfolio, its attractive quality and ...
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
(Corrects bullet 2 and paragraph 5 to say drug is being tested along with GLP-1 treatments, not classified as a GLP-1 drug)(Reuters) -Obesity-focused biotech BioAge Labs said on Wednesday it was ...
Republic Business on MSN10h
Obesity drug developer BioAge seeks up to $587 milllion valuation in US IPOObesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
Check the time stamp on this data. Updated AI-Generated Signals for Global Partners Lp Representing Limited Partner Interests ...
MMLP Martin Midstream Partners L.P.
Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the ...
InMode’s Q2 2024 revenue dropped by 36.5% YoY to $86.4M, underlining macroeconomic challenges. Read why I upgrade INMD stock ...
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with ...
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesisSOLANA BEACH, Calif., Sept.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback